Kipp Davis Email & Phone Number

New York, New York, Us

Joined to oversee financial planning and analysis efforts for high-growth drug discovery pipeline and life science software company. Promoted in 2024 into newly-created role/team to carve out strategic finance deliverables, including oversight of long-range financial planning efforts, pipeline/company valuation, and portfolio decision making to optimize value of growing discovery and clinical pipeline• Lead all aspects of Schrodinger long-range plan, including development of scenarios and analytics to support strategic decisions and deliver on pipeline and financial goals (revenue, cash burn, profitability targets); responsible for long-range financial model, lead and prepare all BOD deliverables• Oversee valuation analysis for R&D projects and software business; lead financial evaluation to assess financial attractiveness/ROI of new BD projects and support prioritization of internal portfolio• Led cross-functional engagement for quarterly and annual operating plan process for $400M+ budget; Contribute to quarterly close, MD&A and BOD deliverables• Implemented new and/or significantly enhanced forecasting processes across business, including forecasting for revenue, expenses/milestones, cash flow; responsible for company KPI analysis

Pittsburgh, Pennsylvania, Us

Joined Viatris through combination of Upjohn, a Pfizer subsidiary, and Mylan Inc. in 2020 into Strategy, Portfolio Decisions and Analysis team.

New York, New York, Us

R&D and budget prioritization• Led cross-functional annual prioritization efforts for ~$3.5B in late-stage R&D spending to optimize return on R&D investment; developed prioritization frameworks, proposed recommended buyup scenarios for endorsement by Portfolio Strategy and Investment Committee• Conducted long-term financial analysis of marketed/development pipeline and led subsequent recommendation (endorsed by Executive Leadership Team) to ringfence over $1B in annual R&D spend to enhance BD efforts and drive Pfizer’s innovative growth strategyPipeline financial analytics• Drove internal modeling efforts to determine optimal portfolio mix (volume, quality) deliver long-term financial targets; recommendations were used to set annual and long-term portfolio goals• Performed various analyses to support company growth and financial objectives, including estimation of end-to-end portfolio IRR, simulations on key productivity metrics (e.g., success rates, cycle times)• Conducted pipeline valuations (NPV/IRR analysis) for multiple products across early- and late-stage development to support the annual budgeting process and go-/no-go decisions (e.g., Phase III start)Corporate and portfolio strategy• Collaborated with Corporate Strategy on pipeline messaging/R&D analytics in Corporate Strategic Plan• Led the business case/analytics supporting strategic decision to exit Neuroscience in late 2017; created the board deliverables supporting the decision presented by ELT to Board of Directors• Led the creation of annual Innovative Pipeline updates presented by head of R&D, head of Global Product Development, and Chief Business Officer to Pfizer Board of Directors

New York, New York, Us

• Led internal advisory efforts across multiple oncology assets to evaluate alternatives to optimize the value of Pfizer’s pipeline (7 compounds, over 20 pipeline indications, and over $10Bn potential sales)• Conducted cross-category analysis evaluating Pfizer’s clinical activity relative to competitors. Results were presented to category presidents and used to support both intra-category and company-wide R&D investment strategy• Supported in-licensing transaction for Bavencio, a novel PD-L1 mAb co-developed with Merck KGaA; conducted comparative financial evaluation of pursuing long-term co-development partnership vs. developing internal late-to-market PD-1 (RN888) as a “go it alone” strategy• Led successful external consultant reviews of two late-stage assets representing $4Bn peak sales

New York, New York, Us

New York, New York, Us

Associate, Corporate and Investment Banking (Global Healthcare Group)• Advised pharma wholesaler Celesio on its successful $8Bn sale to McKesson; developed strategic and financial rationale for the transaction and collaborated with M&A group on development of acquisition model; presented US wholesaler competitive landscape to Celesio CEO• Advised Surgical Care Affiliates on their successful $235Mn IPO; formulated investor materials for IPO roadshow, consulted regularly with CEO and CFO on optimal messaging of strategic and financial highlights• Collaborated with M&A to propose strategic combinations of interest and requisite deal structures to support execution

New York, Ny, Us

Assistant Vice President, U.S. Equity Research (Healthcare Distribution and Technology) • Performed fundamental financial/competitive analysis of healthcare services companies, including financial modeling/forecasting, evaluation of company strategies; team consistently ranked by Institutional Investor• Led the research efforts for the Healthcare IT sector, including writing three company/industry initiation reports and serving as the point person for client engagement regarding Healthcare IT• Interacted regularly with C-suite executives to discuss key strategic and financial issues facing companies and communicated findings/perspectives through written reports and client presentations

New York, New York, Us

New York, New York, Us

• Evaluated hedge fund managers and authored investment recommendation memos for inclusion in Bessemer’s $2.6bn fund platform; assisted with deployment of over $400mm across various strategies• Oversaw all internal and external fund reporting and related statistics/analytics

London, Gb

Commercial Insurance Brokerage

Mba, Accounting, Finance

Bachelor Of Arts (B.A.), Economics

Education record